This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

13 Apr 2021

Pipeline - Clindamycin Product Profile

Clindamycin 150mg/ml Solution for Injection (2ml & 4ml Amp) Dalacin® / Pfizer

Antibacterial.  Serious infections caused by susceptible Gram-positive organisms, staphylococci (both penicillinase- and non-penicillinase-producing), streptococci (except Streptococcus faecalis) and pneumococci.
It is also indicated in serious infections caused by susceptible anaerobic pathogens such as Bacteroides spp, Fusobacterium spp, Propionibacterium spp, Peptostreptococcus spp. and microaerophilic streptococci.
Clindamycin does not penetrate the blood/brain barrier in therapeutically effective quantities.
Dossier Status: On-going / EU CTD Available: 2022
Stability Studies: Zone II / Zone IVb
Shelf life (Originator):   Two (2) years
Batch Sizes: To be defined
Pack Sizes: To be defined   
Originator pack: Box x 1, 5 & 10 Ampoules. 

Mentioned Companies
View company profile